Loading...

PALATIN TECHNOLOGIES INC Product Launches 8-K Filing

PLTN

PALATIN TECHNOLOGIES INC

()

2025 8-K

Show Summary

Summary

Collaboration Agreement

Voluntary Delisting

Voluntary Delisting

Trading Suspension

Equity Offerings

Delisting Notice

Positive Study Results

Securities Offering

Warrant Agreement

Quarterly Results

Delisting Notice

Annual Meeting Notice

Annual Meeting of Stockholders

Material Definitive Agreement

Securities Purchase Agreement

Asset Purchase Agreement

Securities Purchase Agreement

Earnings Reports

Delisting Notice

Clinical Development Progra...

Partnership Announcement

Participation in Conference

Annual Meeting of Stockholders

Presentation Announcement

Conference Call Announcement

Webinar Announcement

Equity Distribution Agreement

External Links:

On March 28 and March 31, 2025, Palatin Technologies announced positive results from Phase 2 studies for its drugs PL8177 and bremelanotide, respectively.

AI Assistant

PALATIN TECHNOLOGIES INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.